Intellia Therapeutics Inc
SWB:38I
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
Intellia Therapeutics Inc
SWB:38I
|
US |
|
A
|
Akwel SA
LSE:0F8V
|
FR |
|
Assa Abloy AB
OTC:ASAZF
|
SE |
|
Toyota Motor Corp
TSE:7203
|
JP |
|
Stellantis NV
MIL:STLAM
|
NL |
|
R
|
Reservoir Media Inc
F:0RL0
|
US |
|
F
|
FibroGen Inc
SWB:1FG
|
US |
|
E
|
Endesa SA
SWB:ENA
|
ES |
|
T
|
TJX Companies Inc
LSE:0LCE
|
US |
|
Grifols SA
OTC:GIKLY
|
ES |
Wall St Price Targets
38I Price Targets Summary
Intellia Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
38I is 24.29 EUR with a low forecast of 7.88 EUR and a high forecast of 86.48 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 38I's stock price target?
Price Target
24.29
EUR
According to Wall Street analysts, the average 1-year price target for
38I is 24.29 EUR with a low forecast of 7.88 EUR and a high forecast of 86.48 EUR.
What is the Revenue forecast for Intellia Therapeutics Inc?
Projected CAGR
51%
Over the last 10 years, the compound annual growth rate for Revenue has been 27%. The projected CAGR for the next 8 years is 51%.